Official Website: Epitel
source confidence: Medium status: Useful updated 2026-06-19
Summary
Epitel's official website describes REMI, a wireless remote EEG monitoring system for healthcare-facility and ambulatory settings, with REMI Vigilenz AI for event detection and integration with Persyst Mobile for physician review.
Useful Claims
- REMI is marketed as a wireless remote EEG monitoring system for near real-time and/or remote EEG in healthcare settings and remote EEG in ambulatory settings.
- The system uses single-use, disposable, wearable sensors that amplify, capture, and wirelessly transmit brain electrical activity for up to 30 days.
- REMI Vigilenz AI for Event Detection is described as software that marks previously acquired EEG sections that may correspond to neurological events of interest indicative of potential electrographic seizures lasting at least 10 seconds; it does not operate in real time and does not provide diagnostic conclusions.
- The site says REMI transmits data to Persyst Mobile and is reimbursable using preexisting codes.
- Indications for use on the site list adult and pediatric patients (1+ years for REMI; 6+ years for Vigilenz AI).
- Epitel lists its address as 465 S. 400 E Suite 250, Salt Lake City, UT 84111.
Verbatim
"The REMI Remote EEG Monitoring System is indicated for use in healthcare settings where near real-time and/or remote EEG is warranted and in ambulatory settings where remote EEG is warranted." — REMI indications for use
"REMI uses single use, single patient, disposable, wearable sensors intended to amplify, capture, and wirelessly transmit a single channel of electrical activity of the brain for a duration up to 30 days." — REMI indications for use
"REMI Vigilenz AI For Event Detection does not mark REMI EEG records in real time and does not provide any diagnostic conclusion about the patient’s condition to the user." — Vigilenz indications for use
Reliability Notes
This is an official company source. FDA indications, reimbursement claims, and clinical-performance statements on a company site are leads, not independent verification. Regulatory status, intended use, and clinical evidence should be confirmed against FDA databases, peer-reviewed publications, and payer policies before being used as high-confidence evidence.